The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
PNPLA3 rs738409 C>G Variant Predicts Fibrosis Progression by Noninvasive Tools in Nonalcoholic Fatty Liver Disease
Grazia Pennisi1, Rosaria Maria Pipitone2, Calogero Cammà2, Vito Di Marco2, Vincenzo Di Martino2, Federica Spatola2, Rossella Zito2, Antonio Craxì2, Stefania Grimaudo2, Salvatore Petta2
Author information
1Section of Gastroenterology and Hepatology, PROMISE, University of Palermo, Palermo, Italy. Electronic address: graziapennisi901@gmail.com.
2Section of Gastroenterology and Hepatology, PROMISE, University of Palermo, Palermo, Italy.
Abstract
Liver fibrosis is the main predictor of events in patients with nonalcoholic fatty liver disease (NAFLD),1 and its evolution is characterized by a nonlinear trend2,3 mostly affected by metabolic risk factors, severity of liver inflammation and steatosis, and weight loss.3 The rs738409 C>G common variant in PNPLA3 gene has been associated with severity of fibrosis and risk of liver-related events in NAFLD.4,5 Noninvasive tests as Fibrosis-4 (FIB-4) and liver stiffness measurement (LSM) are useful to rule-out advanced fibrosis and they could be reliable to predict fibrosis progression.2,6 We aimed to evaluate in patients with NAFLD whether PNPLA3 rs738409 C>G variant impacts on fibrosis progression, noninvasively assessed by FIB-4 and LSM.